Interleukin-15 and the Growth of Tumor Derived Activated T-Cells
- 1 January 1995
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy
- Vol. 10 (1) , 13-20
- https://doi.org/10.1089/cbr.1995.10.13
Abstract
Interleukin-15 was tested to determine whether this recently discovered cytokine was capable of stimulating the growth of tumor derived activated T cells in culture (TDAC, also referred to as tumor infiltrating lymphocytes). When established cultures of IL-2 induced, IL-2 dependent TDAC were tested, IL-15 stimulated growth in a dose dependent manner, alone or in the presence of IL-2. One established TDAC was cultured with IL-15 alone for 18 passages over a 10 week period. Comparing IL-2 and IL-15 treated cultures, growth rate with IL-15 was slower. IL-15 doubled the secreted interferon alpha and granulocyte-macrophage colony stimulating factor. IL-15 and IL-2 were compared in primary TDAC cultures. IL-15 induced TDAC outgrowth in 3 of 6 cultures. IL-2 induced outgrowth in all 6. Tumor cells were eliminated as TDAC grew out in both IL-2 and IL-15 treated cultures. These results suggested that IL-15 like IL-2, is capable of stimulating the growth of TDAC with antitumor activity, but with certain distinct effects which may be of interest therapeutically.Keywords
This publication has 10 references indexed in Scilit:
- Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.The EMBO Journal, 1994
- A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.Proceedings of the National Academy of Sciences, 1994
- Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 ReceptorScience, 1994
- Growth of Tumor Derived Activated T-Cells for the Treatment of CancerCancer Biotherapy, 1994
- Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialCancer, 1991
- Activation and Expansion of Tumor-Derived Activated Cells for Therapeutic UseJNCI Journal of the National Cancer Institute, 1989
- TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCERThe Lancet, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988